Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE28.0900
- TODAY'S CHANGE (%)-0.1200 (-0.4254%)
- Bid / Lots28.0800/ 3
- Ask / Lots28.1000/ 6
- Open / Previous Close28.2500 / 28.2100
- Day Range
- 52 Week Range
- Volume248,414
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPRX |
|---|---|---|
| 09:32 ET | 13373 | 28.225 |
| 09:34 ET | 100 | 28.235 |
| 09:36 ET | 5428 | 28.27 |
| 09:38 ET | 879 | 28.255 |
| 09:39 ET | 2511 | 28.21 |
| 09:41 ET | 200 | 28.215 |
| 09:43 ET | 1045 | 28.215 |
| 09:45 ET | 4932 | 28.18 |
| 09:48 ET | 6476 | 28.19 |
| 09:50 ET | 1741 | 28.175 |
| 09:52 ET | 1027 | 28.156766 |
| 09:54 ET | 200 | 28.15 |
| 09:56 ET | 600 | 28.165 |
| 09:57 ET | 1458 | 28.15 |
| 09:59 ET | 5412 | 28.21 |
| 10:01 ET | 400 | 28.22 |
| 10:03 ET | 9242 | 28.27 |
| 10:06 ET | 2298 | 28.275 |
| 10:08 ET | 1873 | 28.33 |
| 10:10 ET | 612 | 28.335 |
| 10:12 ET | 3748 | 28.325 |
| 10:14 ET | 948 | 28.29 |
| 10:15 ET | 100 | 28.33 |
| 10:17 ET | 920 | 28.35 |
| 10:19 ET | 6546 | 28.32 |
| 10:21 ET | 100 | 28.315 |
| 10:24 ET | 5979 | 28.31 |
| 10:26 ET | 2037 | 28.31 |
| 10:28 ET | 1907 | 28.32 |
| 10:30 ET | 767 | 28.28 |
| 10:32 ET | 2700 | 28.265 |
| 10:33 ET | 1240 | 28.26 |
| 10:35 ET | 3721 | 28.27 |
| 10:37 ET | 3300 | 28.28 |
| 10:39 ET | 4461 | 28.29 |
| 10:42 ET | 700 | 28.295 |
| 10:44 ET | 100 | 28.295 |
| 10:46 ET | 8360 | 28.295 |
| 10:48 ET | 605 | 28.295 |
| 10:50 ET | 1600 | 28.315 |
| 10:51 ET | 2291 | 28.2847 |
| 10:53 ET | 100 | 28.28 |
| 10:55 ET | 1103 | 28.27 |
| 10:57 ET | 1400 | 28.26 |
| 11:00 ET | 5333 | 28.25 |
| 11:02 ET | 2993 | 28.2445 |
| 11:04 ET | 2019 | 28.2 |
| 11:06 ET | 1691 | 28.2 |
| 11:08 ET | 1200 | 28.19 |
| 11:09 ET | 9266 | 28.185 |
| 11:11 ET | 2227 | 28.165 |
| 11:13 ET | 1286 | 28.155 |
| 11:15 ET | 2175 | 28.12 |
| 11:18 ET | 5264 | 28.115 |
| 11:20 ET | 2566 | 28.115 |
| 11:22 ET | 500 | 28.1128 |
| 11:24 ET | 2153 | 28.12 |
| 11:26 ET | 1626 | 28.11 |
| 11:27 ET | 10475 | 28.09 |
| 11:29 ET | 4291 | 28.09 |
| 11:31 ET | 6184 | 28.065 |
| 11:33 ET | 2102 | 28.08 |
| 11:36 ET | 2300 | 28.125 |
| 11:38 ET | 3389 | 28.09 |
Sep 20, 2024
DJ S&P 500 Futures Decline In Premarket Trading; FedEx, Frontline Lag, from 7:30AM ET on Friday Sep 20, 2024 by Dow Jones
7:30AM ET on Friday Sep 20, 2024 by Dow Jones
Sep 18, 2024
DJ S&P 500 Futures Up In Premarket Trading; Manhattan Associates, Casella Waste Sys Lag, from 7:30AM ET on Wednesday Sep 18, 2024 by Dow Jones
7:30AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 3, 2024
Press Release: Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement, from 5:14PM ET on Tuesday Sep 03, 2024 by Dow Jones
5:14PM ET on Tuesday Sep 03, 2024 by Dow JonesRoyalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement, from 5:14PM ET on Tuesday Sep 03, 2024 by Dow Jones
5:14PM ET on Tuesday Sep 03, 2024 by Dow JonesPress Release: Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement, from 5:06PM ET on Tuesday Sep 03, 2024 by Dow Jones
5:06PM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 16.6B | 18.7x | +1.83% |
Amneal Pharmaceuticals Inc | 2.7B | -13.2x | --- |
Endo Inc | 2.0B | 0.4x | --- |
Catalent Inc | 10.9B | -10.5x | --- |
Jazz Pharmaceuticals PLC | 6.7B | 19.2x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Head of Human Capital
- Molly Sawaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.6B |
|---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 2.99% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 09-13-24 |
Beta | 0.46 |
EPS | $1.50 |
Book Value | $14.61 |
P/E Ratio | 18.7x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | 19.7x |
Operating Margin | 42.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
